Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approval for drug production and registration for Peritoneal Dialysis Solution (Bicarbonate-G1.5%) (2000ml) from the National Medical Products Administration of China, being under type 3 chemical drug and regarded as passing the consistency evaluation. It is mainly used for peritoneal dialysis in patients with chronic renal failure, especially when hypermagnesemia has not been adequately improved.

Peritoneal Dialysis Solution (Bicarbonate-G1.5%) is the Group's first dialysis solution product in dual-chamber bag packaging. Using a bicarbonate buffer system, the dual-chamber bag structure allows for isolated storage of different components and immediate mixing before use, but it has a complex manufacturing process and a relatively high technological barrier. This product has a superior biocompatibility, which helps protect peritoneal function and reduces the risk of peritonitis, making it suitable for patients with specific chronic renal failure conditions such as abnormal liver function and metabolic acidosis. As a new and upgraded product in the peritoneal dialysis field, with a limited number of approved manufacturers in China, this product has a favorable competitive landscape, and a differentiated pricing potential compared to traditional lactate preparations. With increasing clinical awareness, there will be ample room for its market penetration.

The Group has a strategic focus on the field of renal replacement therapy, with products covering peritoneal dialysis solution, hemofiltration replacement fluid and others. As an important treatment for end-stage renal disease, peritoneal dialysis offers the convenience of home-based operation and flexible scheduling. It can be used complementarily and sequentially with hemodialysis to prolong patient survival, resulting a robust the clinical demand. Compared to hemodialysis, peritoneal dialysis market penetration rate has a more significant room for improvement in China, indicating a promising future for growth. As of now, the Group has established a leading peritoneal dialysis solution product portfolio in China, covering multiple technical routes including conventional lactate, low-calcium lactate and bicarbonate, as well as various glucose concentrations, making the Group one of the manufacturers with the most complete peritoneal dialysis solution product line in China. Leveraging the Group's mature intravenous infusion technology platform, the system supporting dialysis solution manufacturing is comprehensive, resulting in outstanding quality advantages.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 13 November 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.